# Mativ Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2024

- Company: [Mativ Holdings, Inc.](/companies/matv.md) (CIK 1000623)
- Form: 10-Q
- Filed: 2024-11-12
- Accepted by EDGAR: Nov 12, 2024, 16:20 ET
- Period: 2024-09-30
- Accession: 0001000623-24-000047
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1000623/000100062324000047/matv-20240930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1000623/000100062324000047/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-07-01 to 2024-09-30 | $498.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2024-01-01 to 2024-09-30 | $1.52bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-07-01 to 2024-09-30 | $404.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2024-01-01 to 2024-09-30 | $1.24bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2024-07-01 to 2024-09-30 | $93.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2024-01-01 to 2024-09-30 | $286.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2024-07-01 to 2024-09-30 | $5.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2024-01-01 to 2024-09-30 | $17.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2024-07-01 to 2024-09-30 | $7.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-01-01 to 2024-09-30 | $3.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-07-01 to 2024-09-30 | $18.3m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2024-01-01 to 2024-09-30 | $55.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2024-07-01 to 2024-09-30 | −$3.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-01-01 to 2024-09-30 | −$13.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-07-01 to 2024-09-30 | −$20.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-01-01 to 2024-09-30 | −$50.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-07-01 to 2024-09-30 | −$0.38 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-01-01 to 2024-09-30 | −$0.93 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-07-01 to 2024-09-30 | −$0.38 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-01-01 to 2024-09-30 | −$0.93 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-07-01 to 2024-09-30 | 54,327,500 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-01-01 to 2024-09-30 | 54,305,800 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-01-01 to 2024-09-30 | $70.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-01-01 to 2024-09-30 | $32.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2024-01-01 to 2024-09-30 | $16.2m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2024-01-01 to 2024-09-30 | $800.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2024-09-30 | $162.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-09-30 | $777.3m | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-30 | $2.62bn | us-gaap:Assets |
| Current liabilities | at 2024-09-30 | $328.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-09-30 | $1.74bn | us-gaap:Liabilities |
| Long-term debt | at 2024-09-30 | $1.14bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-09-30 | $2.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2024-09-30 | $882.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 34,738 characters.

*The following is a discussion of our financial condition and results of operations. This discussion should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included elsewhere in this report and the audited consolidated financial statements and related notes and the selected financial data included in our Annual Report on Form 10-K for the year ended December 31, 2023. The discussion of our financial condition and results of operations includes various forward-looking statements about our markets, the demand for our products and our future prospects. These statements are based on certain assumptions we consider reasonable. For information about risks and exposures relating to us and our business, you should read the section entitled "Risk Factors" in Part 1, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, the section entitled "Forward-Looking Statements" at the end of this Item 2 and the section entitled “Risk Factors” at Part II, Item 1A hereof. Unless the context indicates otherwise, references to "Mativ," "we," "us," "our," the "Company" or similar terms include Mativ Holdings, Inc. and our consolidated subsidiaries.*

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our financial statements with an understanding of our recent performance, our financial condition and our prospects.

### Organizational Realignment Plan

As part of the organizational realignment effective during the first quarter of 2024, we reorganized into two new reportable segments: Filtration & Advanced Materials ("FAM") and Sustainable & Adhesive Solutions ("SAS"). Refer to Note 1. General of the Notes to the unaudited Condensed Consolidated Financial Statements for more information on our new segment structure.

All information presented within this MD&A is based on the new segment structure for comparative purposes.

### EP Divestiture

On November 30, 2023 the Company completed the sale of the Engineered Papers business ("EP business"). With the sale of the EP business, Mativ ceased participating in tobacco-based products markets.

The EP business is presented as a discontinued operation for all periods and certain prior period amounts have been retrospectively revised to reflect these changes. The unaudited condensed consolidated financial statements and the notes thereto, unless otherwise indicated, are on a continuing operations basis. Refer to Note 15. Discontinued Operations of the Notes to the unaudited Condensed Consolidated Financial Statements for more information on the discontinued operation and transaction.

This MD&A discusses the financial condition and results of operations of the Company as of and for the three and nine months ended September 30, 2024.

### Liquidity & Debt Overview

As of September 30, 2024, the Company had $1,143.4 million of total debt, $162.2 million of cash, and $300.6 million of undrawn capacity on its $600.0 million revolving line of credit facility (the "Revolving Facility"). Per the terms of the Company's amended credit agreement (the "Amended Credit Agreement"), net leverage was 4.1x at the end of the third quarter, versus a current maximum covenant ratio of 4.50x.

As of September 30, 2024, the Company’s nearest debt maturity was our 6.875% $350.0 million senior unsecured notes which were due October 1, 2026 and were redeemed on October 7, 2024 concurrently with the private placement of our 8.000% $400.0 million senior notes due 2029. For additional information, refer to Note 16. Subsequent Events of the Notes to the unaudited Condensed Consolidated Financial Statements. Our next nearest debt maturities are our Revolving Credit Facility, Term Loan A Facility, and Delayed Draw Term Loan Facility, due on May 6, 2027. Refer to "Liquidity and Capital Resources" section for additional detail.

### SUMMARY

*(in millions, except per share amounts)*

|  | Three Months Ended September 30, 2024 | 2023 | Percent of Net Sales 2024 | 2023 | Nine Months Ended September 30, 2024 | 2023 | Percent of Net Sales 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $498.5 | $498.2 | 100.0% | 100.0% | $1,522.5 | $1,573.7 | 100.0% | 100.0% |
| Gross profit | 93.6 | 86.7 | 18.8% | 17.4% | 286.5 | 269.9 | 18.8% | 17.2% |
| Restructuring & other impairment expense | 11.2 | 16.3 | 2.2% | 3.3% | 37.4 | 17.6 | 2.5% | 1.1% |
| Operating profit (loss) | 7.0 | (419.9) | 1.4% | (84.3)% | 3.7 | (411.7) | 0.2% | (26.2)% |
| Interest expense | 18.3 | 16.8 | 3.7% | 3.4% | 55.0 | 48.8 | 3.6% | 3.1% |
| Income from discontinued operations | — | 9.3 | —% | 1.9% | — | 26.9 | —% | 1.7% |
| Net loss from continuing operations | $(20.8) | $(464.3) | (4.2)% | (93.2)% | $(50.2) | $(494.1) | (3.3)% | (31.4)% |
| Diluted loss per share from continuing operations | $(0.38) | $(8.50) |  |  | $(0.93) | $(9.06) |  |  |
| Cash provided by operations | $37.6 | $32.3 |  |  | $70.7 | $37.8 |  |  |
| Capital spending | $12.1 | $14.7 |  |  | $32.9 | $49.4 |  |  |

30

### RESULTS OF OPERATIONS

### Comparison of the Three Months Ended September 30, 2024 and 2023

### Net Sales

The following table presents net sales by segment for the three months ended September 30, 2024 and 2023 (in millions):

|  | Three Months Ended September 30, 2024 | September 30, 2023 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Filtration & Advanced Materials | $189.6 | $195.8 | $(6.2) | (3.2)% |
| Sustainable & Adhesive Solutions | 308.9 | 302.4 | 6.5 | 2.1% |
| Total | $498.5 | $498.2 | $0.3 | 0.1% |

Consolidated net sales of $498.5 million during the three months ended September 30, 2024 increased $0.3 million or 0.1%, compared to the prior-year quarter.

FAM segment net sales of $189.6 million during the three months ended September 30, 2024 decreased $6.2 million, or 3.2%, compared to the prior-year quarter. The FAM net sales decline reflected lower volumes in advanced films along with lower selling prices, partially offset by higher volumes in filtration & netting.

SAS segment net sales of $308.9 million during the three months ended September 30, 2024 increased $6.5 million, or 2.1%, compared to the prior-year quarter, reflecting higher volumes across all end-markets and higher selling prices, partially offset by sales associated with closed and divested facilities.

### Gross Profit

The following table presents gross profit for the three months ended September 30, 2024 and 2023 (in millions):

|  | Three Months Ended September 30, 2024 | September 30, 2023 | Change | Percent Change 2024 | Percent of Net Sales 2023 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $498.5 | $498.2 | $0.3 | 0.1% | 100.0% | 100.0% |
| Cost of products sold | 404.9 | 411.5 | (6.6) | (1.6)% | 81.2% | 82.6% |
| Gross profit | $93.6 | $86.7 | $6.9 | 8.0% | 18.8% | 17.4% |

Gross profit of $93.6 million during the three months ended September 30, 2024 increased $6.9 million, or 8.0%, compared to the prior-year quarter. The increase in gross profit reflected lower manufacturing costs, partially offset by lower volumes in advanced films and unfavorable mix.

### Nonmanufacturing Expenses

The following table presents nonmanufacturing expenses for the three months ended September 30, 2024 and 2023 (in millions):

|  | Three Months Ended September 30, 2024 | September 30, 2023 | Change | Percent Change 2024 | Percent of Net Sales 2023 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling expense | $18.1 | $20.5 | $(2.4) | (11.7)% | 3.6% | 4.1% |
| Research expense | 5.7 | 5.4 | 0.3 | 5.6% | 1.1% | 1.1% |
| General expense | 51.6 | 63.4 | (11.8) | (18.6)% | 10.4% | 12.7% |
| Nonmanufacturing expenses | $75.4 | $89.3 | $(13.9) | (15.6)% | 15.1% | 17.9% |

Nonmanufacturing expenses of $75.4 million during the three months ended September 30, 2024 decreased $13.9 million, or 15.6%, compared to the prior-year quarter. The decrease is primarily due to 2023 expenses related to the EP Divestiture and integration.

### Restructuring and Other Impairment Expense

The following table presents restructuring and other impairment expense for the three months ended September 30, 2024 and 2023 (in millions):

|  | Three Months Ended September 30, 2024 | September 30, 2023 | Change | Percent of Net Sales 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Filtration & Advanced Materials | $0.7 | $1.1 | $(0.4) | 0.4% | 0.6% |
| Sustainable & Adhesive Solutions | 10.4 | 15.2 | (4.8) | 3.4% | 5.0% |
| Unallocated expenses | 0.1 | — | 0.1 |  |  |
| Total | $11.2 | $16.3 | $(5.1) | 2.2% | 3.3% |

The Company incurred total restructuring and other impairment expense of $11.2 million and $16.3 million in the three months ended September 30, 2024 and 2023, respectively.

Restructuring and other impairment expenses related to the organizational realignment plan (the "Plan") were comprised primarily of severance charges. For the three months ended September 30, 2024, these charges were $0.7 million, of which $0.2 million, $0.5 million and none incurred within FAM, SAS and Unallocated, respectively. For additional information on the Plan, refer to Note 8. Restructuring and Other Impairment Activities of the Notes to the unaudited Condensed Consolidated Financial Statements.

Restructuring and other impairment expenses in the FAM segment, excluding costs associated with the Plan, were primarily due to facility closures announced in prior years.

Restructuring and other impairment expenses in the SAS segment, excluding costs associated with the Plan, included impairment charges of $8.9 million to fully impair the net assets at our Eerbeek, Netherlands facility. The impairment assessment was performed after revising our long-term view on cash flows associated with the facility. The remaining restructuring and other impairment expenses for the three months ended September 30, 2024 were related to a facility closure announced in a prior year.

### Operating Profit (Loss)

The following table presents operating profit (loss) by segment for the three months ended September 30, 2024 and 2023 (in millions):

|  | Three Months Ended September 30, 2024 | September 30, 2023 | Change | Percent Change 2024 | Return on Net Sales 2023 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Filtration & Advanced Materials | $19.9 | $22.6 | $(2.7) | (11.9)% | 10.5% | 11.5% |
| Sustainable & Adhesive Solutions | 10.3 | (405.8) | 416.1 | N.M. | 3.3% | (134.2)% |
| Unallocated expenses | (23.2) | (36.7) | 13.5 | (36.8)% |  |  |
| Total | $7.0 | $(419.9) | $426.9 | N.M. | 1.4% | (84.3)% |

Operating profit of $7.0 million during the three months ended September 30, 2024, increased $426.9 million, compared to the prior year period.

In the FAM segment, operating income was $19.9 million during the three months ended September 30, 2024 reflecting an unfavorable $2.7 million, or 11.9%, change, compared to the prior year period, primarily due to lower volumes in advanced films, and lower selling prices, partially offset by higher volumes in filtration & netting, lower selling and general expenses, and improved manufacturing efficiencies.

In the SAS segment, operating income of $10.3 million during the three months ended September 30, 2024 increased $416.1 million, compared to the prior year period, driven by the 2023 $401.0 million goodwill impairment, decrease in other impairment expense, favorable manufacturing and distribution costs, favorable relative net selling price versus input cost performance, higher volumes, partially offset by unfavorable mix and higher selling and general expenses.

Unallocated expenses of $23.2 million during the three months ended September 30, 2024 decreased $13.5 million, or 36.8%, compared to the prior year period primarily due to the EP Divestiture and integration costs incurred in the prior year period.

### Interest Expense

Interest expense of $18.3 million during the three months ended September 30, 2024 increased $1.5 million, or 8.9%, compared to the prior year period. Interest expense increased primarily due to higher average balances and higher average interest rates on the floating portion of our outstanding debt in 2024.

### Other Expense, Net

Other expense, net was $12.7 million during the three months ended September 30, 2024, compared to the prior year period expense of $0.3 million, primarily driven by other asset related charges and foreign currency losses.

### Income Taxes

A $3.2 million income tax benefit in the three months ended September 30, 2024 resulted in an effective tax rate of 13.3% compared with (6.2)% in the prior year period. The net change was primarily due to mix of earnings in the current period, impact from valuation allowance changes in the current and prior periods, and goodwill impairment not deductible for tax purposes in the prior period.

### Net Loss and Net Loss per Share

Net loss during the three months ended September 30, 2024 was $20.8 million, or $0.38 per diluted share, compared with net loss of $464.3 million, or $8.50 per diluted share, during the prior-year quarter.

### RESULTS OF OPERATIONS

### Comparison of the Nine Months Ended September 30, 2024 and 2023

### Net Sales

The following table presents net sales by segment (in millions):

|  | Nine Months Ended September 30, 2024 | 2023 | Change | Percent Change |
| --- | ---: | ---: | ---: | ---: |
| Filtration & Advanced Materials | $598.7 | $628.1 | $(29.4) | (4.7)% |
| Sustainable & Adhesive Solutions | 923.8 | 945.6 | (21.8) | (2.3)% |
| Total | $1,522.5 | $1,573.7 | $(51.2) | (3.3)% |

Consolidated net sales of $1,522.5 million during the nine months ended September 30, 2024 decreased $51.2 million, or 3.3%, compared to the prior year period.

FAM segment net sales of $598.7 million during the nine months ended September 30, 2024 decreased $29.4 million, or 4.7%, compared to the prior year period primarily due to lower volumes in advanced films, as well as lower selling prices across the segment.

SAS segment net sales of $923.8 million during the nine months ended September 30, 2024 decreased $21.8 million, or 2.3%, compared to the prior year period, reflecting lower volume/mix and lower selling prices, partially offset by favorable currency translation.

### Gross Profit

The following table presents gross profit (in millions):

|  | Nine Months Ended September 30, 2024 | 2023 | Change | Percent Change 2024 | Percent of Net Sales 2023 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $1,522.5 | $1,573.7 | $(51.2) | (3.3)% | 100.0% | 100.0% |
| Cost of products sold | 1,236.0 | 1,303.8 | (67.8) | (5.2)% | 81.2% | 82.8% |
| Gross profit | $286.5 | $269.9 | $16.6 | 6.2% | 18.8% | 17.2% |

Gross profit of $286.5 million during the nine months ended September 30, 2024 increased $16.6 million, or 6.2%, compared to the prior year period. The change in gross profit reflected favorable relative net selling price versus input cost performance, favorable distribution costs, partially offset by lower volume, less favorable product mix, and higher manufacturing costs. The Company monitors and continues to adjust staffing levels of manufacturing labor relative to volumes.

### Nonmanufacturing Expenses

The following table presents nonmanufacturing expenses (in millions):

|  | Nine Months Ended September 30, 2024 | 2023 | Change | Percent Change 2024 | Percent of Net Sales 2023 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling expense | $54.6 | $60.6 | $(6.0) | (9.9)% | 3.6% | 3.9% |
| Research and development expense | 17.5 | 16.6 | 0.9 | 5.4% | 1.1% | 1.1% |
| General expense | 173.3 | 185.8 | (12.5) | (6.7)% | 11.4% | 11.8% |
| Nonmanufacturing expenses | $245.4 | $263.0 | $(17.6) | (6.7)% | 16.1% | 16.7% |

Nonmanufacturing expenses of $245.4 million during the nine months ended September 30, 2024 decreased $17.6 million, or 6.7%, compared to the prior year period primarily driven by integration related costs incurred in the prior year period.

### Restructuring and Other Impairment Expense

The following table presents restructuring and other impairment expense by segment (in millions):

|  | Nine Months Ended September 30, 2024 | 2023 | Change | Percent of Net Sales 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Filtration & Advanced Materials | $5.2 | $2.3 | $2.9 | 0.9% | 0.4% |
| Sustainable & Adhesive Solutions | 28.8 | 15.3 | 13.5 | 3.1% | 1.6% |
| Unallocated expenses | 3.4 | — | 3.4 |  |  |
| Total | $37.4 | $17.6 | $19.8 | 2.5% | 1.1% |

The Company incurred total restructuring and other impairment expense of $37.4 million in the nine months ended September 30, 2024 compared with $17.6 million in the prior year period.

Restructuring and other impairment expenses related to the Plan were comprised primarily of severance charges. For the nine months ended September 30, 2024, these charges were $16.4 million, of which $3.1 million, $10.0 million and $3.3 million incurred within FAM, SAS and Unallocated, respectively. For additional information on the Plan, refer to Note 8. Restructuring and Other Impairment Activities of the Notes to the unaudited Condensed Consolidated Financial Statements.

Restructuring and other impairment expenses in the FAM segment, excluding costs associated with the Plan were due to facility closures announced in prior periods.

Restructuring and other impairment expenses in the SAS segment, excluding costs associated with the Plan included charges of $16.1 million to fully impair the net assets at our Eerbeek, Netherlands facility. The impairment assessment was performed after revising our long-term view on cash flows associated with the facility. The remaining restructuring and other impairment expenses for the nine months ended September 30, 2024 were related to a facility closure announced in a prior year.

### Operating Profit (Loss)

The following table presents operating profit (loss) by segment (in millions):

|  | Nine Months Ended September 30, 2024 | 2023 | Change | Percent Change 2024 | Return on Net Sales 2023 |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Filtration & Advanced Materials | $59.7 | $78.3 | $(18.6) | (23.8)% | 10.0% | 12.5% |
| Sustainable & Adhesive Solutions | 30.1 | (385.4) | 415.5 | N.M. | 3.3% | (40.8)% |
| Unallocated expenses | (86.1) | (104.6) | (18.5) | (17.7)% |  |  |
| Total | $3.7 | $(411.7) | $415.4 | N.M. | 0.2% | (26.2)% |

Operating profit of $3.7 million during the nine months ended September 30, 2024 increased $415.4 million compared to the prior year period.

In the FAM segment, operating income of $59.7 million during the nine months ended September 30, 2024 decreased $18.6 million, or 23.8%, compared to the prior year period primarily due to lower volumes in advanced films and higher manufacturing costs.

In the SAS segment, operating income was $30.1 million during the nine months ended September 30, 2024 reflecting a $415.5 million increase, compared to the prior year period, driven by the $401.0 million goodwill impairment in 2023, favorable relative net selling price versus input cost performance, and favorable distribution and manufacturing expenses, partially offset by lower volume/mix and higher selling and general expenses.

Unallocated expenses of $86.1 million during the nine months ended September 30, 2024 decreased $18.5 million, or 17.7% compared to the prior year period primarily due to integration related costs incurred in the prior year period.

### Interest Expense

Interest expense of $55.0 million during the nine months ended September 30, 2024 increased $6.2 million, or 12.7%, compared to the prior year period. Interest expense increased primarily due to higher average interest rates and higher average balances on the floating portion of our outstanding debt in 2024.

### Other Expense, Net

Other expense, net of $12.1 million during the nine months ended September 30, 2024 decreased $8.5 million, compared to the prior year period, primarily driven by other asset related charges and foreign currency losses.

### Income Taxes

A $13.2 million income tax benefit in the nine months ended September 30, 2024 resulted in an effective tax rate of 20.8% compared with (6.5)% in the prior year period. The net change was primarily due to mix of earnings in the current period, impact from valuation allowance changes in the current and prior periods, and goodwill impairment not deductible for tax purposes in the prior period.

### Net Loss and Net Loss per Share

Net loss during the nine months ended September 30, 2024 was $50.2 million, or $0.93 per diluted share, compared to net loss of $494.1 million, or $9.06 per diluted share, during the prior year period.

### LIQUIDITY AND CAPITAL RESOURCES

A major factor in our liquidity and capital resource planning is our generation of cash flow from operations, which is sensitive to changes in the mix of products sold, volume and pricing of our products, as well as changes in our production volumes, costs and working capital. Our liquidity is supplemented by funds available under our Revolving Facility with a syndicate of banks that is used as either operating conditions or strategic opportunities warrant. Market conditions permitting, we may also seek to access the capital markets as we deem appropriate.

#### Cash Requirements

As of September 30, 2024, $134.5 million of the Company's $162.2 million of cash and cash equivalents was held by foreign subsidiaries. We believe our sources of liquidity and capital, including cash on-hand, cash generated from operations, our Revolving Facility, and our Receivables Sales Agreement (an off-balance sheet arrangement as defined in Item 303(a)(4)(ii) of SEC Regulation S-K), will be sufficient to finance our continued operations, our current and long-term growth plan, and dividend payments.

#### Working Capital

As of September 30, 2024, the Company had net operating working capital of $452.1 million, including cash and cash equivalents of $162.2 million, compared to net operating working capital of $433.9 million, including cash and cash equivalents of $120.2 million as of December 31, 2023. The increase was attributable primarily to an increase in accounts receivable and cash and cash equivalents, partially offset by an increase in accounts payable and accrued liabilities and other current liabilities.

### Cash Provided By Operating Activities

Net cash provided by operating activities was $70.7 million during the nine months ended September 30, 2024 compared to net cash provided of $37.8 million during the prior year period. The increase was attributable to lower net loss adjusted for non-cash items and favorable year-over-year movements in working capital related cash flows.

During the nine months ended September 30, 2024, net changes in operating working capital resulted in cash inflows of $0.8 million, an increase from $13.4 million of outflows during the prior year period. The $14.2 million increase was due to an increase in net changes of accounts payable and other current liabilities, partially offset by a decrease in net changes of inventories and accounts receivable.

### Cash Used In Investing Activities

Cash used in investing activities during the nine months ended September 30, 2024 was $29.4 million, compared to cash outflows of $49.4 million during the prior year period, primarily attributable to changes in capital spending and proceeds from sale of assets. Within investing cash flows, capital spending was $32.9 million compared to $49.4 million in the prior year period.

### Cash Provided By (Used In) Financing Activities

Cash provided by financing activities during the nine months ended September 30, 2024 was $12.2 million, compared to cash used of $13.2 million during the prior year period. During the nine months ended September 30, 2024, financing activities primarily consisted of $127.0 million of borrowings under the Revolving Facility, $16.2 million of dividends paid to the Company's stockholders, and payments on our long-term debt of $97.0 million.

During the prior year period, financing activities primarily consisted of $180.0 million of proceeds from borrowings under the Revolving Facility, $134.2 million of payments on our long-term debt, and $49.8 million of dividends paid to the Company's stockholders.

The Company presently believes the sources of liquidity discussed above are sufficient to meet our anticipated funding needs for the foreseeable future.

### Dividends and Share Repurchases

On November 6, 2024, we announced a cash dividend of $0.10 per share payable on December 20, 2024 to stockholders of record as of November 29, 2024. The covenants contained in the Indenture governing the Notes and Amended Credit Agreement require that we maintain certain financial ratios as disclosed in Note 9. Debt of the notes to the unaudited condensed consolidated financial statements, none of which under normal business conditions materially limit our ability to pay such dividends. We will continue to assess our dividend policy in light of our overall strategy, cash generation, debt levels and ongoing requirements for cash to fund operations and to pursue possible strategic opportunities.

### Debt Instruments and Related Covenants

The following table presents activity related to our debt instruments for the nine months ended September 30, 2024 and 2023 (in millions):

| 2024 | Nine Months Ended September 30, 2023 |  |
| --- | ---: | ---: |
| Proceeds from long-term debt | $127.0 | $180.0 |
| Payments on long-term debt | (97.0) | (134.2) |
| Net proceeds from borrowings | $30.0 | $45.8 |

Net proceeds from borrowings were $30.0 million during the nine months ended September 30, 2024, compared to net proceeds from borrowings of $45.8 million during the prior year period.

Unused borrowing capacity under the Amended Credit Agreement was $300.6 million as of September 30, 2024.

The Company was in compliance with all of its covenants under the Indenture and Amended Credit Agreement at September 30, 2024. With the current level of borrowing and forecasted results, we expect to remain in compliance with financial covenants under the Amended Credit Agreement.

Our total debt to capital ratios, as calculated under the Amended Credit Agreement, at September 30, 2024 and December 31, 2023 were 56.4% and 53.8%, respectively.

### Critical Accounting Policies and Estimates

The preparation of our unaudited condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make judgments, assumptions and estimates that affect the amounts reported. There have been no material changes to the critical accounting policies and estimates described in our Form 10-K for the 2023 fiscal year ended December 31, 2023.

For further information about our critical accounting policies, please see the discussion of critical accounting policies in our Annual Report on Form 10-K for the year ended December 31, 2023 in the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Estimates."

### FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") that are subject to the safe harbor created by the Act and other legal protections. Forward-looking statements include, without limitation, those regarding the incurrence of additional debt and expected maturities of the Company’s debt obligations, the adequacy of our sources of liquidity and capital, acquisition integration and growth prospects, the cost and timing of our restructuring actions, our expectations regarding our organizational realignment plan, the impact of ongoing litigation matters and environmental claims, the amount of capital spending and/or common stock repurchases, future cash flows, purchase accounting impacts, impacts and timing of our ongoing operational excellence and other cost-reduction and cost-optimization initiatives, profitability, and cash flow, the expected benefits and accretion of the Neenah merger and integration, whether the strategic benefits of the EP Divestiture can be achieved and other statements generally identified by words such as "believe," "expect," "intend," "guidance," "plan," "forecast," "potential," "anticipate," "confident," "project," "appear," "future," "should," "likely," "could," "may," "will," "typically" and similar words.

These forward-looking statements are prospective in nature and not based on historical facts, but rather on current expectations and on numerous assumptions regarding the business strategies and the environment in which the Company’s business shall operate in the future and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that may cause actual results to differ materially from our expectations as of the date of this report. These risks include, among other things, those set forth in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2023, and otherwise in our reports and filings with the Securities and Exchange Commission ("SEC"), as well as the following factors:

- Risks associated with the implementation of our strategic growth initiatives, including diversification, and the Company's understanding of, and entry into, new industries and technologies;
- Risks associated with acquisitions, dispositions, strategic transactions and global asset realignment initiatives of Mativ, including the recent EP Divestiture;
- Adverse changes in our end-market sectors impacting key customers;
- Changes in the source and intensity of competition in our commercial end-markets;
- Adverse changes in sales or production volumes, pricing and/or manufacturing costs;
- Seasonal or cyclical market and industry fluctuations which may result in reduced net sales and operating profits during certain periods;
- Risks associated with our technological advantages in our intellectual property and the likelihood that our current technological advantages are unable to continue indefinitely;
- Supply chain disruptions, including the failure of one or more material suppliers, including energy, resin, fiber, and chemical suppliers, to supply materials as needed to maintain our product plans and cost structure;
- Increases in operating costs due to inflation and continuing increases in the inflation rate or otherwise, such as labor expense, compensation and benefits costs;
- Our ability to attract and retain key personnel, labor shortages, labor strikes, stoppages or other disruptions;
- Changes in general economic, financial and credit conditions in the U.S., Europe, China and elsewhere, including the impact thereof on currency exchange rates (including any weakening of the Euro) and on interest rates;
- A failure in our risk management and/or currency or interest rate swaps and hedging programs, including the failures of any insurance company or counterparty;
- Changes in the manner in which we finance our debt and future capital needs, including potential acquisitions;
- Changes in tax rates, the adoption of new U.S. or international tax legislation or exposure to additional tax liabilities;
- Uncertainty as to the long-term value of the common stock of Mativ;
- Changes in employment, wage and hour laws and regulations in the U.S. and elsewhere, including unionization rules and regulations by the National Labor Relations Board, equal pay initiatives, additional anti-discrimination rules or tests and different interpretations of exemptions from overtime laws;
- The impact of tariffs, and the imposition of any future additional tariffs and other trade barriers, and the effects of retaliatory trade measures;
- Existing and future governmental regulation and the enforcement thereof that may materially restrict or adversely affect how we conduct business and our financial results;
- Weather conditions, including potential impacts, if any, from climate change, known and unknown, and natural disasters or unusual weather events;
- International conflicts and disputes, such as the ongoing conflict between Russia and Ukraine, the war between Israel and Hamas and the broader regional conflict in the Middle East, which restrict our ability to supply products into affected regions, due to the corresponding effects on demand, the application of international sanctions, or practical consequences on transportation, banking transactions, and other commercial activities in troubled regions;
- Compliance with the FCPA and other anti-corruption laws or trade control laws, as well as other laws governing our operations;
- Risks associated with pandemics and other public health emergencies, including the COVID-19 pandemic and its variant strains;
- The number, type, outcomes (by judgment or settlement) and costs of legal, tax, regulatory or administrative proceedings, litigation and/or amnesty programs;
- Increased scrutiny from stakeholders related to environmental, social and governance ("ESG") matters, as well as our ability to achieve our broader ESG goals and objectives;
- Costs and timing of implementation of any upgrades or changes to our information technology systems;
- Failure by us to comply with any privacy or data security laws or to protect against theft of customer, employee and corporate sensitive information;
- Information technology system failures, data security breaches, network disruptions, and cybersecurity events; and
- Other factors described elsewhere in this document and from time to time in documents that we file with the SEC.

All forward-looking statements made in this document are qualified by these cautionary statements. Forward-looking statements herein are made only as of the date of this document, and we do not undertake any obligation, other than as may be required by law, to update or revise any forward-looking or cautionary statements to reflect changes in assumptions, the occurrence of events, unanticipated or otherwise, or changes in future operating results over time or otherwise.

Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance unless expressed as such and should only be viewed as historical data.

## Market risk

As filed, 325 characters.

Our market risk exposure at September 30, 2024 is consistent with, and not materially different than, the market risk and discussion of exposure presented under the caption "Quantitative and Qualitative Disclosures about Market Risk" in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2023.

## Controls and procedures

As filed, 1,208 characters.

### Evaluation of Disclosure Controls and Procedures

We currently have in place systems relating to disclosure controls and procedures designed to ensure the timely recording, processing, summarizing and reporting of information required to be disclosed in periodic reports under the Securities Exchange Act of 1934, as amended. These disclosure controls and procedures include those designed to ensure that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions about required disclosure. Upon completing our review and evaluation of the effectiveness of our disclosure controls and procedures as of September 30, 2024, our Chief Executive Officer and Chief Financial Officer have concluded that these controls and procedures were effective as of September 30, 2024.

### Changes in Internal Control Over Financial Reporting

No changes in our internal control over financial reporting were identified as having occurred in the fiscal quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 771 characters.

There have been no material changes to the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2023. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, "Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Filed Nov 12, 2024.
Source: SEC EDGAR, the filing index for accession 0001000623-24-000047. Last ingested by Listed: Nov 5, 2026, 16:53 ET. No prices; not investment advice.
